MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1 + adults immunized with influenza seasonal vaccine

Daniela Fenoglio, M. R. Zocchi, A. Parodi, P. Durando, G. Gabutti, R. Gasparini, A. Poggi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction. We previously reported that in HIV-1 infected patients circulating Vdelta1 T lymphocytes (Vδ1) increase and proliferate in vitro in response to Candida albicans (Ca). Herein, we analysed the effects of MF59 adjuvant on the Vδ1 T cell responses to hemagglutinin (HA) and Ca in HIV-1 seropositive and seronegative adults after influenzal vaccine, to clarify the molecular mechanisms triggered in vivo by an adjuvanted vaccine against influenza virus. Materials and methods. 58 seropositive (HIV-1 +) and 48 seronegative (HIV-1-) subjects received influenzal vaccines containing or not the MF59 adjuvant. The follow-up of in vitro T cell proliferation and cytokine production (IL-17A, IL-22, IL-23, IL-6) to HA and Ca antigens were performed at different time points (at basal time and after 30 and 90 days from vaccination) by cytofluorimetric approaches. Results. We confirmed that in HIV-1 infected individuals the Vδ1 T cell subset is expanded in HIV-1 infected individuals and moreover the number of circulating Vδ1 T cells significantly enhanced in all HIV-1 + subjects on day 90 after influenza vaccination. Regard the follow-up of proliferative responses, the increments of CD3 + response to HA and Vδ1 T cells to Ca in HIV-1 + individuals were detectable earlier on day 30 for MF59-vaccinated patients, instead on day 90 post-vaccination in HIV +-vaccinated without MF59 adjuvant. Of note, production of IL-17A and IL-22, two cytokines with anti-fungal activity, in response to Ca was enhanced (for IL-17A) or restored (for IL-22) by vaccination in HIV-1 + donors, mainly using the MF59-adjuvanted vaccine. Moreover, after vaccination IL-23 and IL-6 production increased in response to HA in the HIV + and HIV- groups vaccinated with MF59 adjuvant. Conclusions. We suggest that in HIV-1 infected patients the circulating Vδ1 T lymphocytes reactive to Ca upon challenge with influenza virus vaccine receive an activating/enhancing signal mediated by cytokines triggered by the boost with HA antigen particularly in presence of MF59 adjuvant.

Original languageEnglish
Pages (from-to)137-141
Number of pages5
JournalJournal of Preventive Medicine and Hygiene
Volume52
Issue number3
Publication statusPublished - Sep 2011

Fingerprint

Influenza Vaccines
HIV-1
T-Lymphocytes
Candida albicans
Hemagglutinins
Vaccination
Interleukin-17
Interleukin-23
Vaccines
HIV
Cytokines
Interleukin-6
Antigens
T-Lymphocyte Subsets
MF59 oil emulsion
Human Influenza
Cell Proliferation
Tissue Donors

Keywords

  • Gammadelta T cells
  • HIV-1
  • Inflammatory cytokines

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1 + adults immunized with influenza seasonal vaccine. / Fenoglio, Daniela; Zocchi, M. R.; Parodi, A.; Durando, P.; Gabutti, G.; Gasparini, R.; Poggi, A.

In: Journal of Preventive Medicine and Hygiene, Vol. 52, No. 3, 09.2011, p. 137-141.

Research output: Contribution to journalArticle

@article{f2ed8b8fc7d04ec1b0c3c379c8b5b930,
title = "MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1 + adults immunized with influenza seasonal vaccine",
abstract = "Introduction. We previously reported that in HIV-1 infected patients circulating Vdelta1 T lymphocytes (Vδ1) increase and proliferate in vitro in response to Candida albicans (Ca). Herein, we analysed the effects of MF59 adjuvant on the Vδ1 T cell responses to hemagglutinin (HA) and Ca in HIV-1 seropositive and seronegative adults after influenzal vaccine, to clarify the molecular mechanisms triggered in vivo by an adjuvanted vaccine against influenza virus. Materials and methods. 58 seropositive (HIV-1 +) and 48 seronegative (HIV-1-) subjects received influenzal vaccines containing or not the MF59 adjuvant. The follow-up of in vitro T cell proliferation and cytokine production (IL-17A, IL-22, IL-23, IL-6) to HA and Ca antigens were performed at different time points (at basal time and after 30 and 90 days from vaccination) by cytofluorimetric approaches. Results. We confirmed that in HIV-1 infected individuals the Vδ1 T cell subset is expanded in HIV-1 infected individuals and moreover the number of circulating Vδ1 T cells significantly enhanced in all HIV-1 + subjects on day 90 after influenza vaccination. Regard the follow-up of proliferative responses, the increments of CD3 + response to HA and Vδ1 T cells to Ca in HIV-1 + individuals were detectable earlier on day 30 for MF59-vaccinated patients, instead on day 90 post-vaccination in HIV +-vaccinated without MF59 adjuvant. Of note, production of IL-17A and IL-22, two cytokines with anti-fungal activity, in response to Ca was enhanced (for IL-17A) or restored (for IL-22) by vaccination in HIV-1 + donors, mainly using the MF59-adjuvanted vaccine. Moreover, after vaccination IL-23 and IL-6 production increased in response to HA in the HIV + and HIV- groups vaccinated with MF59 adjuvant. Conclusions. We suggest that in HIV-1 infected patients the circulating Vδ1 T lymphocytes reactive to Ca upon challenge with influenza virus vaccine receive an activating/enhancing signal mediated by cytokines triggered by the boost with HA antigen particularly in presence of MF59 adjuvant.",
keywords = "Gammadelta T cells, HIV-1, Inflammatory cytokines",
author = "Daniela Fenoglio and Zocchi, {M. R.} and A. Parodi and P. Durando and G. Gabutti and R. Gasparini and A. Poggi",
year = "2011",
month = "9",
language = "English",
volume = "52",
pages = "137--141",
journal = "Journal of Preventive Medicine and Hygiene",
issn = "1121-2233",
publisher = "Pacini Editore s.r.l.",
number = "3",

}

TY - JOUR

T1 - MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1 + adults immunized with influenza seasonal vaccine

AU - Fenoglio, Daniela

AU - Zocchi, M. R.

AU - Parodi, A.

AU - Durando, P.

AU - Gabutti, G.

AU - Gasparini, R.

AU - Poggi, A.

PY - 2011/9

Y1 - 2011/9

N2 - Introduction. We previously reported that in HIV-1 infected patients circulating Vdelta1 T lymphocytes (Vδ1) increase and proliferate in vitro in response to Candida albicans (Ca). Herein, we analysed the effects of MF59 adjuvant on the Vδ1 T cell responses to hemagglutinin (HA) and Ca in HIV-1 seropositive and seronegative adults after influenzal vaccine, to clarify the molecular mechanisms triggered in vivo by an adjuvanted vaccine against influenza virus. Materials and methods. 58 seropositive (HIV-1 +) and 48 seronegative (HIV-1-) subjects received influenzal vaccines containing or not the MF59 adjuvant. The follow-up of in vitro T cell proliferation and cytokine production (IL-17A, IL-22, IL-23, IL-6) to HA and Ca antigens were performed at different time points (at basal time and after 30 and 90 days from vaccination) by cytofluorimetric approaches. Results. We confirmed that in HIV-1 infected individuals the Vδ1 T cell subset is expanded in HIV-1 infected individuals and moreover the number of circulating Vδ1 T cells significantly enhanced in all HIV-1 + subjects on day 90 after influenza vaccination. Regard the follow-up of proliferative responses, the increments of CD3 + response to HA and Vδ1 T cells to Ca in HIV-1 + individuals were detectable earlier on day 30 for MF59-vaccinated patients, instead on day 90 post-vaccination in HIV +-vaccinated without MF59 adjuvant. Of note, production of IL-17A and IL-22, two cytokines with anti-fungal activity, in response to Ca was enhanced (for IL-17A) or restored (for IL-22) by vaccination in HIV-1 + donors, mainly using the MF59-adjuvanted vaccine. Moreover, after vaccination IL-23 and IL-6 production increased in response to HA in the HIV + and HIV- groups vaccinated with MF59 adjuvant. Conclusions. We suggest that in HIV-1 infected patients the circulating Vδ1 T lymphocytes reactive to Ca upon challenge with influenza virus vaccine receive an activating/enhancing signal mediated by cytokines triggered by the boost with HA antigen particularly in presence of MF59 adjuvant.

AB - Introduction. We previously reported that in HIV-1 infected patients circulating Vdelta1 T lymphocytes (Vδ1) increase and proliferate in vitro in response to Candida albicans (Ca). Herein, we analysed the effects of MF59 adjuvant on the Vδ1 T cell responses to hemagglutinin (HA) and Ca in HIV-1 seropositive and seronegative adults after influenzal vaccine, to clarify the molecular mechanisms triggered in vivo by an adjuvanted vaccine against influenza virus. Materials and methods. 58 seropositive (HIV-1 +) and 48 seronegative (HIV-1-) subjects received influenzal vaccines containing or not the MF59 adjuvant. The follow-up of in vitro T cell proliferation and cytokine production (IL-17A, IL-22, IL-23, IL-6) to HA and Ca antigens were performed at different time points (at basal time and after 30 and 90 days from vaccination) by cytofluorimetric approaches. Results. We confirmed that in HIV-1 infected individuals the Vδ1 T cell subset is expanded in HIV-1 infected individuals and moreover the number of circulating Vδ1 T cells significantly enhanced in all HIV-1 + subjects on day 90 after influenza vaccination. Regard the follow-up of proliferative responses, the increments of CD3 + response to HA and Vδ1 T cells to Ca in HIV-1 + individuals were detectable earlier on day 30 for MF59-vaccinated patients, instead on day 90 post-vaccination in HIV +-vaccinated without MF59 adjuvant. Of note, production of IL-17A and IL-22, two cytokines with anti-fungal activity, in response to Ca was enhanced (for IL-17A) or restored (for IL-22) by vaccination in HIV-1 + donors, mainly using the MF59-adjuvanted vaccine. Moreover, after vaccination IL-23 and IL-6 production increased in response to HA in the HIV + and HIV- groups vaccinated with MF59 adjuvant. Conclusions. We suggest that in HIV-1 infected patients the circulating Vδ1 T lymphocytes reactive to Ca upon challenge with influenza virus vaccine receive an activating/enhancing signal mediated by cytokines triggered by the boost with HA antigen particularly in presence of MF59 adjuvant.

KW - Gammadelta T cells

KW - HIV-1

KW - Inflammatory cytokines

UR - http://www.scopus.com/inward/record.url?scp=80052939927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052939927&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 137

EP - 141

JO - Journal of Preventive Medicine and Hygiene

JF - Journal of Preventive Medicine and Hygiene

SN - 1121-2233

IS - 3

ER -